In this downloadable slideset, John L. Marshall, MD, discusses the current data on using MMRd/MSI status to select patients for treatment with immune checkpoint inhibitors across all solid tumors.
In this downloadable slideset, Giuseppe Giaccone, MD, PhD, discusses the current data on using PD-L1 status to select patients for treatment with immune checkpoint inhibitors in solid tumors.
In this downloadable slideset, Michael J. Pishvaian, MD, PhD, discusses the current data on using BRCA mutation status to identify patients for treatment with PARP inhibitors in select solid tumors.
In this downloadable slideset, Axel Grothey, MD, discusses the current data on optimal treatment options for patients with cancer and BRAF, MAPK, or HER2 alterations.
In this downloadable slideset, Todd M. Bauer, MD, discusses the current data on optimal treatment options for patients with NTRK, ROS1, FGFR, or RET altered tumors.
Are you up to date on the latest information on targeting RET alterations in patients with NSCLC and other malignancies?
Gain insights on the clinical role of BRCA1/2 mutations with this downloadable PDF summarizing genetic risk evaluation, approved therapies, and companion diagnostics for breast, ovarian, pancreatic, and prostate cancers.
Consult this PDF resource to gain clinical insights on recently approved indications and emerging biomarkers in multiple malignancies, including PIK3CA, PDFGRα, KIT, MET, and KRASG12C.
Gain clinical insights on FGFR alterations in multiple malignancies, including FDA-approved and investigational agents, and current testing approaches with this PDF resource.
Review this PDF resource for clinical insights on the use of HER2 alterations in various malignancies, along with current FDA-approved indications and companion diagnostics in breast cancer and gastric/gastroesophageal junction cancer.
Download this PDF featuring clinical insights, approved therapies, and available assays for MSI-high/MMR-deficient colorectal cancer and other solid tumors.
Gain clinical insights on FDA-approved immunotherapy indications and complementary diagnostics for PD-L1 in multiple malignancies with this PDF resource.
Download this PDF resource for clinical insights on BRAF mutations, from types of mutations to FDA-approved agents and companion diagnostics, in multiple solid tumors.
Download this PDF clinical resource reviewing investigational RET inhibitors and testing strategies for RET alterations in thyroid cancer, NSCLC, and other malignancies.
Get up to date on the clinical role of ROS1 rearrangements in nonsquamous NSCLC, including FDA-approved targeted therapies and diagnostic methods, with this downloadable PDF resource.
Review this PDF resource summarizing FDA-approved and investigational TRK inhibitors and testing platforms for NTRK fusions in multiple malignancies.
Watch this on-demand Webcast from our live symposium to review the latest clinical data and expert perspectives on using biomarkers to select therapy for your patients with solid tumors.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.